WEBULL
WebtradeDownload

Is Biogen (BIIB) Fully Priced After Earnings Raised Revenue But Cut Profit?

Simply Wall St · 1d ago

Earnings event in focus for Biogen stock

Biogen (BIIB) is back in the spotlight after its second quarter 2026 earnings. The company reported higher sales and revenue, alongside a sharp drop in net income and earnings per share.

See our latest analysis for Biogen.

The latest earnings have arrived after a period of stronger momentum for Biogen, with a 16.0% year to date share price return and a 61.47% total shareholder return over the past year, despite weaker three and five year total returns.

If you are looking beyond Biogen for other potential ideas in healthcare related technology, this could be a good moment to review a curated list of 42 healthcare AI stocks

Biogen now combines a long established drug portfolio with mixed recent earnings and a sharp share price rebound. The question is whether that track record and pipeline are already fully reflected in the current valuation.

Most Popular Narrative: 9.4% Undervalued

Biogen's last close at $206.28 sits below the most widely followed fair value estimate of $227.59, which is built on detailed long term earnings and margin forecasts.

Demand for Biogen's Alzheimer's therapy LEQEMBI is poised for structural long-term growth, supported by a rapidly aging global population and accelerating rates of mild cognitive impairment diagnoses facilitated by breakthroughs in blood-based biomarkers and expanding diagnostic infrastructure. These factors position Biogen to capture a larger patient pool and drive sustained revenue expansion.

Read the complete narrative.

Curious what sits behind that confidence in LEQEMBI and the wider pipeline? The narrative leans on specific revenue paths, margin shifts and a future earnings multiple that together build this fair value case.

Result: Fair Value of $227.59 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, the Biogen story can change quickly if key launches like LEQEMBI or ZURZUVAE underperform expectations, or if competition and pricing pressure erode core MS revenues.

Find out about the key risks to this Biogen narrative.

Another View on Biogen's Valuation

While the analyst fair value of $227.59 suggests Biogen is 9.4% undervalued, the current P/E of 36.5x paints a different picture. It sits much higher than the US Biotechs industry at 17.1x, peers at 21.9x, and even the estimated fair ratio of 29x. That premium raises a simple question: How much optimism are you really paying for?

See what the numbers say about this price — find out in our valuation breakdown.

NasdaqGS:BIIB P/E Ratio as at Aug 2026
NasdaqGS:BIIB P/E Ratio as at Aug 2026

Next Steps

With mixed signals around Biogen's earnings and valuation, this is a good moment to move quickly, review the full picture, and weigh both sides of the story. To see those key red flags alongside the potential bright spots, start by checking the 2 key rewards and 2 important warning signs.

Looking for more investment ideas beyond Biogen?

You have seen how complex Biogen can be. Do not stop there, because a wider watchlist can help you spot opportunities before they are crowded.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.